دورية أكاديمية
أعرض في EDS

Evaluation of pneumococcal and influenza vaccination coverage in rheumatology patients receiving biological therapy in a regional referral hospital.

التفاصيل البيبلوغرافية
العنوان: Evaluation of pneumococcal and influenza vaccination coverage in rheumatology patients receiving biological therapy in a regional referral hospital.
عنوان ترانسليتريتد: Evaluación de las coberturas de vacunación antineumocócica y antigripal en pacientes reumatológicos con terapia biológica de un hospital autonómico de referencia.
المؤلفون: Fernández-Prada M; Unidad de Vacunas, Servicio de Medicina Preventiva y Salud Pública, Hospital Universitario Central de Asturias, Oviedo, Asturias, España., Brandy-García AM; Servicio de Reumatología, Hospital Universitario Central de Asturias, Oviedo, Asturias, España. Electronic address: anahymbg@gmail.com., Rodríguez-Fonseca OD; Servicio de Medicina Nuclear, Hospital Universitario Central de Asturias, Oviedo, Asturias, España., Huerta-González I; Servicio de Vigilancia Epidemiológica, Dirección General de Salud Pública, Consejería de Sanidad del Principado de Asturias, Oviedo, Asturias, España., Fernández-Noval F; Servicio de Vigilancia Epidemiológica, Dirección General de Salud Pública, Consejería de Sanidad del Principado de Asturias, Oviedo, Asturias, España., Martínez-Ortega C; Servicio de Medicina Preventiva y Salud Pública, Hospital Universitario Valle del Nalón, Riaño, Asturias, España.
المصدر: Reumatologia clinica [Reumatol Clin (Engl Ed)] 2020 Mar - Apr; Vol. 16 (2 Pt 1), pp. 97-102. Date of Electronic Publication: 2018 May 08.
نوع المنشور: Journal Article
اللغة: English; Spanish; Castilian
بيانات الدورية: Publisher: Elsevier Doyma Country of Publication: Spain NLM ID: 101717526 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2173-5743 (Electronic) Linking ISSN: 21735743 NLM ISO Abbreviation: Reumatol Clin (Engl Ed) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Barcelona?] : Elsevier Doyma
مواضيع طبية MeSH: Biological Therapy* , Influenza Vaccines* , Pneumococcal Vaccines*, Influenza, Human/*prevention & control , Pneumococcal Infections/*prevention & control , Rheumatic Diseases/*complications , Vaccination Coverage/*statistics & numerical data, Adult ; Aged ; Aged, 80 and over ; Cross-Sectional Studies ; Female ; Humans ; Immunocompromised Host ; Influenza, Human/immunology ; Logistic Models ; Male ; Middle Aged ; Multivariate Analysis ; Patient Compliance/psychology ; Patient Compliance/statistics & numerical data ; Pneumococcal Infections/immunology ; Referral and Consultation ; Rheumatic Diseases/drug therapy ; Rheumatic Diseases/immunology
مستخلص: Objective: Vaccination coverage for seasonal influenza and pneumococcus in rheumatology patients receiving biological treatment. To identify variables that predict vaccination adherence.
Material and Method: Descriptive cross-sectional study. The study involved rheumatology patients who initiated biological therapy between 01/01/2016 and 12/31/2016 in a regional referral hospital. Variables included sociodemographic information, diagnostic data, treating physician, referral to the vaccine unit and vaccination against pneumococcus with 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23), as well as seasonal influenza (2016/17). Univariate, bivariate (Chi-square) and multivariate analysis (logistic regression) were performed. The differences were considered significant (P<.05) and the PASW v.18 software package was used.
Results: In all, 222 patients were included. Vaccination coverage was: PCV13, 80.2%; PPSV23, 77.9%; influenza 2016/17, 78.8%; PCV13+PPSV23, 75.2%; PCV13+PPSV23+influenza 2016/17, 68.9%. Axial spondylitis had the highest coverage (>80%) for pneumococcal vaccination and combination of pneumococcal with influenza. Overall, 27% of the patients were not referred to the unit. The treating physician was associated with statistical significance in each vaccine alone or combined, but referral to the vaccine unit was independently associated with the highest vaccination coverage (P<.001) in all cases.
Conclusions: Compared to the scientific literature, we consider that the coverage of our patients against pneumococcus and influenza is high. Referral of these patients to the vaccine unit is the key to guarantee a correct immunization and to minimize some of the possible infectious adverse effects of biological therapies.
(Copyright © 2018 Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. Publicado por Elsevier España, S.L.U. All rights reserved.)
فهرسة مساهمة: Keywords: Biological therapy; Gripe; Influenza; Neumococo; Pneumococcus; Terapia biológica; Vaccine; Vacuna
المشرفين على المادة: 0 (Influenza Vaccines)
0 (Pneumococcal Vaccines)
تواريخ الأحداث: Date Created: 20180513 Date Completed: 20210315 Latest Revision: 20210525
رمز التحديث: 20231215
DOI: 10.1016/j.reuma.2018.03.009
PMID: 29752214
قاعدة البيانات: MEDLINE
الوصف
تدمد:2173-5743
DOI:10.1016/j.reuma.2018.03.009